Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5479
-0.0256-4.46%
Volume:4.90M
Turnover:2.67M
Market Cap:133.14M
PE:-0.73
High:0.5904
Open:0.5800
Low:0.5314
Close:0.5735
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:1.92
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-12.81
PE(LYR):-0.31

Loading ...

Outlook Therapeutics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
May 18

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Outlook Therapeutics Q2 adjusted EPS misses analyst expectations

Reuters
·
May 16

Outlook Therapeutics Q2 Adjusted EPS USD -0.16

THOMSON REUTERS
·
May 16

Outlook Therapeutics Inc - Completes FDA Dispute Resolution Meeting for Ons-5010; Decision Expected in May 2026

THOMSON REUTERS
·
May 16

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 16

BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing

Reuters
·
May 14

Outlook Therapeutics Inc - Enters Atm Offering Agreement With H.c. Wainwright for up to $100 Mln - SEC Filing

THOMSON REUTERS
·
May 14

Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright

Reuters
·
May 14

Outlook Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 11

Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share

Reuters
·
Apr 24

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Dow Jones
·
Apr 24

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

TIPRANKS
·
Apr 22

Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31

Reuters
·
Apr 22

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Apr 22

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

TIPRANKS
·
Apr 22

BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)

Reuters
·
Apr 21

Outlook Therapeutics Inc - Expects FDA Feedback in May 2026

THOMSON REUTERS
·
Apr 21

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Benzinga_recent_news
·
Apr 08

Outlook Therapeutics submits formal dispute resolution request to FDA

TIPRANKS
·
Apr 07